Recent Insider Transactions • Jun 07
Independent Director recently sold €245k worth of stock On the 4th of June, Hilda Scharen-Guivel sold around 3k shares on-market at roughly €81.72 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.9m more than they bought in the last 12 months. Announcement • Apr 27
IRADIMED CORPORATION to Report Q1, 2026 Results on May 01, 2026 IRADIMED CORPORATION announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 01, 2026 Announcement • Feb 05
IRADIMED CORPORATION to Report Q4, 2025 Results on Feb 10, 2026 IRADIMED CORPORATION announced that they will report Q4, 2025 results Pre-Market on Feb 10, 2026 Announcement • Dec 09
Iradimed Corporation Approves Special Cash Dividend on Outstanding Common Stock, Payable on December 30, 2025 iRadimed Corporation announced that its Board of Directors approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. Announcement • Oct 28
IRADIMED CORPORATION to Report Q3, 2025 Results on Nov 03, 2025 IRADIMED CORPORATION announced that they will report Q3, 2025 results Pre-Market on Nov 03, 2025 Announcement • Sep 03
IRADIMED CORPORATION Announces Board Changes IRADIMED CORPORATION announced a Board of Directors transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after deciding it is time to step away following many years of dedicated service. Effective September 2, 2025, the Board has appointed Joe Kiani, Masimo founder and renowned medical technology innovator and entrepreneur, to fill the vacancy on the Board. Anthony Vuoto served as a director of Iradimed since 2016, providing valuable strategic guidance during a period of significant growth and innovation for the Company. Joining the Board is Joe Kiani, an industry pioneer with a distinguished track record in medical technology. Mr. Kiani is the founder of Masimo Corporation, where he served as Chairman and CEO from 1989 until 2024, growing the company into a global leader in non-invasive patient monitoring technologies, particularly pulse oximetry. Mr. Kiani is also the CEO of Willow Laboratories, a health and wellness innovator, and Like Minded Labs, a company focused on advanced video technologies, and he serves on the Board of Directors of CDX Medical Technologies, an early-stage respiratory care company. With over 500 patents or patent applications and a reputation for driving innovation, Mr. Kiani brings critical expertise to the Board. Mr. Kiani’s Board appointment is effective September 2, 2025, and he will serve on the Board’s audit committee and chairman of the compensation committee, helping to guide Iradimed’s growth in the medical device sector. Announcement • Jul 26
IRADIMED CORPORATION to Report Q2, 2025 Results on Aug 01, 2025 IRADIMED CORPORATION announced that they will report Q2, 2025 results Pre-Market on Aug 01, 2025 Announcement • May 29
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System Iradimed Corporation announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium®? 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with first-generation device in 2005. The MRidium®? 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imaging. TheMRidium®? 3870 features a non-magnetic ultrasonic pump motor, non-interfering RF emissions, and non-ferrous components, ensuring seamless performance in high-magnetic-field environments. Building on Iradimed's legacy of innovation, this next-generation system introduces an enhanced, intuitive graphical touchscreen user interface and advanced safety features. The 3870 can operate independently or be combined with additional 3870 pumps to operate as a four-channel IV infusion pump system for critical care patients. The 3870 also features a modern drug library solution that accommodates multiple patient care area drug listing, facilitating use in a wide variety of MRI applications and patient needs. These 3870 enhancements address the evolving needs of healthcare providers, driving patient safety and workflow efficiency during MRI scans. Iradimed plans a strategic rollout of the newly FDA-cleared MRidium®? 3870 infusion pump with initial unit deployment to select healthcare facilities in the fourth quarter of 2025. Material shipments growing towards full commercial distribution will ramp throughout 2026. Announcement • May 01
IRADIMED CORPORATION, Annual General Meeting, Jun 19, 2025 IRADIMED CORPORATION, Annual General Meeting, Jun 19, 2025. Location: 1025 willa springs drive, winter springs, florida 32708, United States Announcement • Apr 28
IRADIMED CORPORATION to Report Q1, 2025 Results on May 05, 2025 IRADIMED CORPORATION announced that they will report Q1, 2025 results Pre-Market on May 05, 2025 Announcement • Feb 14
IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend for the First Quarter of 2025, Payable on March 5, 2025 IRADIMED CORPORATION announced increase in quarterly cash dividend from $0.15 to $0.17 per share. The Company’s board of directors declared a regular quarterly cash dividend of $0.17 per common share for the first quarter of 2025, of outstanding common stock, payable on March 5, 2025, to stockholders of record as of the close of business on February 24, 2025. Announcement • Feb 13
IRADIMED CORPORATION Provides Earnings Guidance for the First Quarter and Full Year 2025 IRADIMED CORPORATION provided earnings guidance for the first quarter and full year 2025. For the quarter, Company expected revenue of $19.2 million to $19.4 million, and GAAP diluted earnings per share of $0.35 to $0.39.
For the full year, Company expected to report revenue of $78.0 million to $82.0 million, GAAP diluted earnings per share of $1.55 to $1.65. Announcement • Jan 30
IRADIMED CORPORATION to Report Q4, 2024 Results on Feb 13, 2025 IRADIMED CORPORATION announced that they will report Q4, 2024 results Pre-Market on Feb 13, 2025 Announcement • Jan 11
IRADIMED CORPORATION Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 IRADIMED CORPORATION provided earnings guidance for the fourth quarter and full year 2024. The company anticipates total revenue for the fourth quarter of 2024 to be in the range of approximately $19.2 million to $19.4 million, representing year-over-year growth of between 10% and 11% and sequential quarter-over-quarter growth of between 5% and 6%.
Full-year 2024 total revenue is expected to be in the range of approximately $73.1 million to $73.3 million, compared to $65.6 million in the prior year period, representing year-over-year growth of between 11% and 12%. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €52.50, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total returns to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €94.47 per share. Upcoming Dividend • Nov 08
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 15 November 2024. Payment date: 25 November 2024. Payout ratio is a comfortable 31% and the cash payout ratio is 80%. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.8%). Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.40 in 3Q 2023) Third quarter 2024 results: EPS: US$0.40 (down from US$0.40 in 3Q 2023). Revenue: US$18.3m (up 11% from 3Q 2023). Net income: US$5.05m (flat on 3Q 2023). Profit margin: 28% (down from 31% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Oct 25
IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024 IRADIMED CORPORATION announced that they will report Q3, 2024 results Pre-Market on Oct 31, 2024 Upcoming Dividend • Aug 13
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 20 August 2024. Payment date: 30 August 2024. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.9%). Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: US$0.39 (vs US$0.33 in 2Q 2023) Second quarter 2024 results: EPS: US$0.39 (up from US$0.33 in 2Q 2023). Revenue: US$17.9m (up 11% from 2Q 2023). Net income: US$4.90m (up 17% from 2Q 2023). Profit margin: 27% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Jul 25
IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024 IRADIMED CORPORATION announced that they will report Q2, 2024 results Pre-Market on Aug 01, 2024 Recent Insider Transactions • Jun 06
Independent Director recently sold €78k worth of stock On the 3rd of June, Monty Allen sold around 2k shares on-market at roughly €39.84 per share. This transaction amounted to 9.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €191k more than they bought in the last 12 months. Reported Earnings • May 03
First quarter 2024 earnings released: EPS: US$0.33 (vs US$0.27 in 1Q 2023) First quarter 2024 results: EPS: US$0.33 (up from US$0.27 in 1Q 2023). Revenue: US$17.6m (up 14% from 1Q 2023). Net income: US$4.14m (up 21% from 1Q 2023). Profit margin: 24% (up from 22% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • May 03
IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024 IRADIMED CORPORATION’s Board of Directors declared a regular quarterly cash dividend of $0.15 per share of outstanding common stock, payable on May 30, 2024 to stockholders of record as of the close of business on May 20, 2024. Announcement • May 01
IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024 IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024, at 10:00 Eastern Daylight. Location: 1025 Willa Springs Drive, Winter Springs Florida United States Agenda: To elect the directors until the 2025 annual meeting of stockholders and until his successor is duly elected and shall qualify, or until his earlier death, resignation, disqualification or removal; to ratify the appointment of rsm us llp as the independent registered public accounting firm of the company for the year ending December 31, 2024; and to approve, on a non-binding advisory basis, the fiscal 2023 compensation of the company’s named executive officers. Announcement • Apr 28
IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024 IRADIMED CORPORATION announced that they will report Q1, 2024 results Pre-Market on May 02, 2024 Reported Earnings • Mar 04
Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022) Full year 2023 results: EPS: US$1.36 (up from US$1.02 in FY 2022). Revenue: US$65.6m (up 23% from FY 2022). Net income: US$17.2m (up 34% from FY 2022). Profit margin: 26% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 09
Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022) Full year 2023 results: EPS: US$1.36 (up from US$1.02 in FY 2022). Revenue: US$65.6m (up 23% from FY 2022). Net income: US$17.2m (up 34% from FY 2022). Profit margin: 26% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Announcement • Feb 08
IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024 IRadimed Corporation provided revenue guidance for the first quarter and full year of 2024. For the period, the company expects to report revenue of $17.0 million to $17.3 million, GAAP diluted earnings per share of $0.29 to $0.31.For the year, the company expects to report revenue of $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62. Announcement • Feb 02
IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024 IRadimed Corporation announced that they will report Q4, 2023 results Pre-Market on Feb 08, 2024 Recent Insider Transactions • Nov 14
Independent Director recently sold €114k worth of stock On the 13th of November, Anthony Vuoto sold around 3k shares on-market at roughly €37.20 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €258k more than they bought in the last 12 months. Reported Earnings • Nov 05
Third quarter 2023 earnings released: EPS: US$0.40 (vs US$0.27 in 3Q 2022) Third quarter 2023 results: EPS: US$0.40 (up from US$0.27 in 3Q 2022). Revenue: US$16.5m (up 23% from 3Q 2022). Net income: US$5.07m (up 48% from 3Q 2022). Profit margin: 31% (up from 26% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Announcement • Nov 04
Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 IRadimed Corporation provided earnings guidance for the fourth quarter and full year 2023. For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38.For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37. Announcement • Oct 27
IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023 IRadimed Corporation announced that they will report Q3, 2023 results Pre-Market on Nov 03, 2023 Announcement • Aug 04
IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023 IRadimed Corporation provided earnings guidance for the third quarter and for the full year of 2023. For the quarter, the company expects to report revenue of $16.1 million to $16.3 million, GAAP diluted earnings per share of $0.33 to $0.35.For the year, the company now expects to report revenue of $64.5 million to $65.5 million, GAAP diluted earnings per share of $1.25 to $1.28. Reported Earnings • Aug 04
Second quarter 2023 earnings released: EPS: US$0.33 (vs US$0.26 in 2Q 2022) Second quarter 2023 results: EPS: US$0.33 (up from US$0.26 in 2Q 2022). Revenue: US$16.1m (up 27% from 2Q 2022). Net income: US$4.18m (up 29% from 2Q 2022). Profit margin: 26% (in line with 2Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Announcement • Jul 29
IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023 IRadimed Corporation announced that they will report Q2, 2023 results Pre-Market on Aug 03, 2023 Recent Insider Transactions • May 11
Independent Director recently sold €117k worth of stock On the 10th of May, Monty Allen sold around 3k shares on-market at roughly €41.93 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €257k more than they bought in the last 12 months. Reported Earnings • May 05
First quarter 2023 earnings released: EPS: US$0.27 (vs US$0.20 in 1Q 2022) First quarter 2023 results: EPS: US$0.27 (up from US$0.20 in 1Q 2022). Revenue: US$15.5m (up 26% from 1Q 2022). Net income: US$3.41m (up 37% from 1Q 2022). Profit margin: 22% (up from 20% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €32.80, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total returns to shareholders of 45% over the past three years. Reported Earnings • Feb 05
Full year 2022 earnings released: EPS: US$1.02 (vs US$0.76 in FY 2021) Full year 2022 results: EPS: US$1.02 (up from US$0.76 in FY 2021). Revenue: US$53.3m (up 28% from FY 2021). Net income: US$12.8m (up 38% from FY 2021). Profit margin: 24% (up from 22% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Feb 03
Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023 The Board of Directors of IRadimed Corporation approved a special cash dividend of $1.05 per share. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. Announcement • Jan 27
IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023 IRadimed Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 02, 2023 Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €32.40, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total returns to shareholders of 42% over the past three years. Announcement • Jan 20
IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023 IRadimed Corporation provided earnings guidance For the first quarter of 2023 and full year 2023. For the period, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. Reported Earnings • Nov 04
Third quarter 2022 earnings released: EPS: US$0.27 (vs US$0.21 in 3Q 2021) Third quarter 2022 results: EPS: US$0.27 (up from US$0.21 in 3Q 2021). Revenue: US$13.4m (up 23% from 3Q 2021). Net income: US$3.43m (up 33% from 3Q 2021). Profit margin: 26% (up from 24% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 10% per year. Recent Insider Transactions • Aug 06
Independent Director recently sold €113k worth of stock On the 4th of August, Monty Allen sold around 3k shares on-market at roughly €36.86 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.1m more than they bought in the last 12 months. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Jim Hawkins was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 30
Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.12 in 2Q 2021) Second quarter 2022 results: EPS: US$0.26 (up from US$0.12 in 2Q 2021). Revenue: US$12.7m (up 30% from 2Q 2021). Net income: US$3.24m (up 121% from 2Q 2021). Profit margin: 26% (up from 15% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 16%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Jul 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Jim Hawkins was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorated over the past week After last week's 23% share price decline to €30.20, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 30x in the Medical Equipment industry in Germany. Total returns to shareholders of 25% over the past year. Reported Earnings • May 02
First quarter 2022 earnings released: EPS: US$0.20 (vs US$0.11 in 1Q 2021) First quarter 2022 results: EPS: US$0.20 (up from US$0.11 in 1Q 2021). Revenue: US$12.3m (up 34% from 1Q 2021). Net income: US$2.49m (up 79% from 1Q 2021). Profit margin: 20% (up from 15% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 19%, compared to a 11% growth forecast for the industry in Germany. Recent Insider Transactions • Feb 13
COO, CFO & Secretary recently sold €846k worth of stock On the 11th of February, Christopher Scott sold around 19k shares on-market at roughly €43.89 per share. This was the largest sale by an insider in the last 3 months. This was Christopher's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improved over the past week After last week's 34% share price gain to €45.80, the stock trades at a forward P/E ratio of 59x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 122% over the past year. Recent Insider Transactions • Dec 14
Independent Director recently sold €785k worth of stock On the 7th of December, James Hawkins sold around 19k shares on-market at roughly €41.88 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €903k more than they bought in the last 12 months. Recent Insider Transactions • Nov 06
Independent Director recently sold €119k worth of stock On the 3rd of November, Anthony Vuoto sold around 4k shares on-market at roughly €32.14 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €159k more than they bought in the last 12 months. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS US$0.21 (vs US$0.088 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$10.9m (up 42% from 3Q 2020). Net income: US$2.58m (up 140% from 3Q 2020). Profit margin: 24% (up from 14% in 3Q 2020). Reported Earnings • Jul 31
Second quarter 2021 earnings released: EPS US$0.12 (vs US$0.17 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.81m (up 44% from 2Q 2020). Net income: US$1.47m (up US$3.58m from 2Q 2020). Profit margin: 15% (up from net loss in 2Q 2020). Reported Earnings • May 04
First quarter 2021 earnings released: EPS US$0.11 (vs US$0.15 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: US$9.22m (up 6.3% from 1Q 2020). Net income: US$1.39m (down 22% from 1Q 2020). Profit margin: 15% (down from 20% in 1Q 2020). Reported Earnings • Feb 06
Full year 2020 earnings released: EPS US$0.11 (vs US$0.85 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$31.7m (down 18% from FY 2019). Net income: US$1.37m (down 86% from FY 2019). Profit margin: 4.3% (down from 25% in FY 2019). The decrease in margin was primarily driven by lower revenue. Analyst Estimate Surprise Post Earnings • Feb 06
Revenue beats expectations Revenue exceeded analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 10%, compared to a 14% growth forecast for the Medical Equipment industry in Germany. Is New 90 Day High Low • Feb 04
New 90-day high: €21.40 The company is up 12% from its price of €19.10 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period. Reported Earnings • Nov 08
Third quarter 2020 earnings released: EPS US$0.088 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$7.70m (down 23% from 3Q 2019). Net income: US$1.07m (down 56% from 3Q 2019). Profit margin: 14% (down from 25% in 3Q 2019). The decrease in margin was driven by lower revenue. Analyst Estimate Surprise Post Earnings • Nov 08
Revenue beats expectations Revenue exceeded analyst estimates by 3.2%. Over the next year, revenue is forecast to stay flat compared to a 13% growth forecast for the Medical Equipment industry in Germany. Is New 90 Day High Low • Nov 03
New 90-day high: €19.40 The company is up 2.0% from its price of €19.10 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 3.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of US$3.97m, down 51% from the prior year. Total revenue was US$34.1m over the last 12 months, down 5.4% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 30
Third-quarter earnings released: Revenue beats expectations Third-quarter revenue exceeded analyst estimates by 3.2% at US$7.70m. Revenue is forecast to grow 14% over the next year, compared to a 11% growth forecast for the Medical Equipment industry in Germany. 